How the Evidence Balances Heart Rate Changes against Cardiovascular Outcomes While semaglutide raises resting heart rate mildly, several trials report cardiovascular event benefits for GLP-1 receptor agonists as a class in people with established cardiovascular disease
ICH Q2(R2) states that analytical procedures should be evaluated for characteristics such as specificity, selectivity, range, accuracy, precision, and robustness where applicable [13]
The liver is responsible for breaking down hormones like estrogen
Recurrence and metastases are possible
The idea is that microdosing can: Reduce side effects: Its common to experience side effects when taking GLP-1s, especially gastrointestinal issues including nausea, vomiting, and diarrhea
Clinically, we are seeing that some patients report a reduced sense of reward from certain behaviors